# EDGAR Filing Document

**Accession Number:** 0000885725
**File Stem:** 0000885725-23-000004
**Filing Date:** 2023-2
**Character Count:** 58312
**Document Hash:** 7e8af4641a7aea7e0fcdeb78ad82a571
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000885725-23-000004.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0000885725-23-000004

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230201

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BOSTON SCIENTIFIC CORP
- **CENTRAL INDEX KEY:** 0000885725
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 042695240
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11083
- **FILM NUMBER:** 23574687

**BUSINESS ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234
- **BUSINESS PHONE:** 508-683-4000

**MAIL ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234

?xml version="1.0" ? bsx-20230201

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

<u>_____________________________________________________________________</u>

**FORM 8-K** 

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934** 

**<u>_____________________________________________________________________</u>**

Date of Report (Date of earliest event reported): February 1, 2023

**<u>BOSTON SCIENTIFIC CORPORATION</u>** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>1-11083</u>** | **<u>04-2695240</u>** |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**&nbsp;&nbsp;&nbsp;&nbsp;<u>300 Boston Scientific Way</u>, <u>Marlborough</u>, <u>Massachusetts</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>01752-1234</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Address of Principal Executive Offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; (Zip Code)

Registrant's telephone number, including area code: **508 683-4000** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value per share | BSX | New York Stock Exchange |
| 0.625% Senior Notes due 2027 | BSX27 | New York Stock Exchange |
| 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share | BSX PR A | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**ITEM 2.02.&nbsp;&nbsp;&nbsp;&nbsp;RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On February 1, 2023, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2022. A copy of the release is furnished with this report as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

**ITEM 9.01. &nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits

**Exhibit No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description**

99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Press Release issued by Boston Scientific Corporation dated February 1, 2023](q42022earningsrelease.htm)</u>

104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;document

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | |
|:---|:---|:---|:---|
| Date: | February 1, 2023 | BOSTON SCIENTIFIC CORPORATION | BOSTON SCIENTIFIC CORPORATION |
|  |  | By: | /s/ Susan Thompson |
|  |  |  | Susan Thompson |
|  |  |  | Vice President, Chief Corporate Counsel, and Assistant Secretary |

---

## Exhibit 99.1

![imagea.jpg](imagea.jpg)

**FOR IMMEDIATE RELEASE**

**BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR**

**FOURTH QUARTER AND FULL YEAR 2022**

Marlborough, Mass. (February 1, 2023) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational<sup>1</sup> basis and 7.1 percent on an organic<sup>2</sup> basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions<sup>3</sup>. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted<sup>4</sup> EPS of $0.45 for the period, which includes an approximate $0.04 negative impact of the Italian payback, compared to $0.45 a year ago.

For the full year 2022, the company generated net sales of $12.682 billion, growing 6.7 percent on a reported basis, 11.1 percent on an operational<sup>1</sup> basis and 8.7 percent on an organic<sup>2</sup> basis, including a negative 50 basis point impact associated with the Italian government payback provisions, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $642 million or $0.45 per share, compared to $985 million or $0.69 per share a year ago, and delivered full year adjusted<sup>4</sup> EPS of $1.71, including the approximate $0.04 negative impact of the Italian payback, compared to $1.63 a year ago.

"Our global team continues living our mission to transform lives, and I'm proud of the results we achieved in the fourth quarter and throughout 2022," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "In the year ahead we remain committed to our goals of delivering new, meaningful innovations to benefit patients globally while continuing to deliver differentiated financial performance."

**Fourth quarter financial results and recent developments:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reported net sales of $3.242 billion, representing an increase of 3.7 percent on a reported basis, compared to the company's guidance range of 2 to 4 percent; 8.7 percent on an operational basis; and 7.1 percent on an organic basis, compared to the company's guidance range of 7 to 9 percent, all compared to the prior year period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reported GAAP net income available to common stockholders of $0.09 per share, compared to the company's guidance range of $0.23 to $0.28 per share, and achieved adjusted EPS of $0.45 per share, compared to the guidance range of $0.45 to $0.48 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Achieved the following net sales growth in each reportable segment<sup>5</sup>, compared to the prior year period:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ MedSurg: 4.4 percent reported, 8.5 percent operational and organic

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Cardiovascular: 6.4 percent reported, 12.1 percent operational and 9.4 percent organic

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Achieved the following net sales growth/(declines) in each region, compared to the prior year period:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ U.S.: 10.5 percent reported and operational

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ EMEA (Europe, Middle East and Africa): (0.8) percent reported and 10.8 percent operational

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ APAC (Asia-Pacific): (4.1) percent reported and 9.8 percent operational

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ LACA (Latin America and Canada): 14.6 percent reported and 17.7 percent operational

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Emerging Markets<sup>7</sup>: 11.6 percent reported and 23.3 percent operational

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the **AGENT™ Drug Coated Balloon (DCB)** in Japan to treat patients with in-stent restenosis (ISR) and coronary small vessel disease (SVD), with launch anticipated in the first half of this year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Completed enrollment in the CHAMPION-AF clinical trial, a randomized, head-to-head study with 3,000 patients evaluating the safety and efficacy of the **WATCHMAN FLX™ Left Atrial Appendage Closure Device** compared to non-vitamin K antagonist oral anticoagulants for stroke prevention in a broad population of patients with non-valvular atrial fibrillation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Completed enrollment in the SOLIS randomized clinical trial to assess **WaveWriter Spinal Cord Stimulator Systems** (SCS) for the treatment of patients with chronic low back and/or leg pain who have not undergone spinal surgery (NSBP, Non-Surgical Back Pain/VB, Virgin Back). The study met its primary endpoint; SCS demonstrated superior outcomes compared with Conventional Medical Management at three-month follow-up.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Began enrollment in the ACURATE Prime XL Nested Registry, which is designed to assess outcomes from patients receiving the larger **ACURATE Prime™ Aortic Valve XL** within the ACURATE IDE clinical study in the U.S. Also announced, at PCR London Valves, late-breaking data from the European ACURATE neo2 Post Market Clinical Follow-up study supporting the clinical procedural success and safety of the **ACURATE neo2™ Aortic Valve System** to treat patients with severe aortic stenosis, including a high procedural success rate and low rates of mortality and paravalvular leak.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Presented positive data from the ELEGANCE registry during a late-breaking presentation at the 2022 Vascular InterVentional Advances (VIVA) conference, which highlighted that the study is currently exceeding its goal to increase the representation of women and underrepresented minorities in clinical trials for drug-eluting peripheral therapies. Patients enrolled in the registry will be followed for up to five years, allowing for the evaluation of long-term outcomes and the gathering of critical clinical insights into underrepresented patient populations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) , subject to customary closing conditions, to expand the Boston Scientific endoluminal surgery portfolio and enable a measured entry into the endobariatric market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced strategic investment to acquire majority stake in Acotec Scientific Holdings Limited, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures, subject to customary closing conditions.

*1. Operational net sales growth excludes the impact of foreign currency fluctuations.*

*2*. *Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.*

*3. Unplanned reserves established in connection with the activation of the Italian government payback provision, aimed at rationalizing public spending and requiring medical device companies to pay back a portion of spend exceeding allocated healthcare budgets.*

*4. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items.*

*5. In the first quarter of 2022, we reorganized our operational structure and have aggregated our core businesses, each of which generate revenues from the sale of medical devices, into two reportable segments comprised of MedSurg and Cardiovascular. Within the Cardiovascular segment, the newly formed Cardiology division represents the combined former Rhythm Management and Interventional Cardiology businesses*. *We have revised prior period amounts to conform to the current year presentation.* 

*6. In 2022, reflects sales reserves established for Italian government payback provisions, not allocated to reportable segments. In 2021, includes net sales associated with Specialty Pharmaceuticals prior to the sale of the business on March 1, 2021. Specialty Pharmaceuticals net sales were substantially U.S. based and presented as a stand-alone operating segment alongside our medical device reportable segments.*

*7. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.*

**Fourth Quarter Net Sales by Business and Region:** 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | **Change** | **Change** | **Change** | **Change** | **Change** |
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational Basis** | **Less: Impact of Recent Acquisitions / Divestitures** | **Organic Basis** |
|<br>*(in millions)* | **2022** | **2021** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational Basis** | **Less: Impact of Recent Acquisitions / Divestitures** | **Organic Basis** |
| &nbsp;&nbsp;&nbsp;&nbsp;Endoscopy | $571 | $558 | 2.4% | (5.1)% | 7.4% | —% | 7.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Urology | 477 | 441 | 8.2% | (3.6)% | 11.8% | —% | 11.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Neuromodulation | 249 | 244 | 2.1% | (2.8)% | 4.9% | —% | 4.9% |
| **MedSurg**<sup>5</sup> | **1297** | **1243** | **4.4%** | **(4.1)%** | **8.5%** | —% | **8.5%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cardiology | 1529 | 1422 | 7.5% | (5.6)% | 13.2% | 3.6% | 9.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Peripheral Interventions | 476 | 462 | 3.0% | (5.8)% | 8.8% | —% | 8.8% |
| **Cardiovascular**<sup>5</sup> | **2005** | **1884** | **6.4%** | **(5.7)%** | **12.1%** | **2.7%** | **9.4%** |
|  | **3302** | **3127** | **5.6%** | **(5.0)%** | **10.7%** | **1.6%** | **9.0%** |
| &nbsp;&nbsp;Other<sup>6</sup> | (60) |  | (100.0)% | —% | (100.0)% | —% | (100.0)% |
| **Net Sales** | $**3242** | $**3127** | **3.7%** | **(5.0)%** | **8.7%** | **1.6%** | **7.1%** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | **Change** | **Change** | **Change** |
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational<br> Basis** |
|<br>*(in millions)* | **2022** | **2021** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational<br> Basis** |
| &nbsp;&nbsp;&nbsp;U.S. | $1986 | $1798 | 10.5% | —% | 10.5% |
| &nbsp;&nbsp;&nbsp;EMEA | 657 | 662 | (0.8)% | (11.6)% | 10.8% |
| &nbsp;&nbsp;&nbsp;APAC | 536 | 559 | (4.1)% | (13.9)% | 9.8% |
| &nbsp;&nbsp;&nbsp;LACA | 122 | 107 | 14.6% | (3.1)% | 17.7% |
|  | **3302** | **3127** | **5.6%** | **(5.0)%** | **10.7%** |
| &nbsp;&nbsp;Other<sup>6</sup> | (60) |  | (100.0)% | —% | (100.0)% |
| **Net Sales** | $**3242** | $**3127** | **3.7%** | **(5.0)%** | **8.7%** |
| **Emerging Markets**<sup>7</sup> | $**445** | $**398** | **11.6%** | **(11.7)%** | **23.3%** |

---

*Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.*

*Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions / divestitures are not prepared in accordance with U.S. GAAP.*

**Full Year Net Sales by Business and Region:** 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | **Change** | **Change** | **Change** | **Change** | **Change** |
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational Basis** | **Less: Impact of Recent Acquisitions / Divestitures** | **Organic Basis** |
|<br>*(in millions)* | **2022** | **2021** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational Basis** | **Less: Impact of Recent Acquisitions / Divestitures** | **Organic Basis** |
| &nbsp;&nbsp;&nbsp;&nbsp;Endoscopy | $2221 | $2141 | 3.7% | (4.4)% | 8.1% | —% | 8.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Urology | 1773 | 1583 | 12.0% | (2.9)% | 14.9% | 5.3% | 9.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Neuromodulation | 917 | 909 | 0.9% | (2.6)% | 3.5% | —% | 3.5% |
| **MedSurg**<sup>5</sup> | **4911** | **4633** | **6.0%** | **(3.5)%** | **9.5%** | **1.8%** | **7.7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cardiology | 5932 | 5422 | 9.4% | (5.1)% | 14.5% | 4.0% | 10.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Peripheral Interventions | 1899 | 1820 | 4.4% | (4.8)% | 9.1% | —% | 9.1% |
| **Cardiovascular**<sup>5</sup> | **7831** | **7242** | **8.1%** | **(5.0)%** | **13.1%** | **3.0%** | **10.1%** |
|  | **12742** | **11875** | **7.3%** | **(4.4)%** | **11.7%** | **2.5%** | **9.2%** |
| &nbsp;&nbsp;Other<sup>6</sup> | (60) | 13 | (+100)% | —% | (+100)% | —% | (+100)% |
| **Net Sales** | $**12682** | $**11888** | **6.7%** | **(4.4)%** | **11.1%** | **2.4%** | **8.7%** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | **Change** | **Change** | **Change** |
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational<br> Basis** |
|<br>*(in millions)* | **2022** | **2021** | **Reported Basis** | **Less: Impact of Foreign Currency Fluctuations** | **Operational<br> Basis** |
| &nbsp;&nbsp;&nbsp;U.S. | $7632 | $6901 | 10.6% | —% | 10.6% |
| &nbsp;&nbsp;&nbsp;EMEA | 2526 | 2518 | 0.3% | (12.1)% | 12.4% |
| &nbsp;&nbsp;&nbsp;APAC | 2116 | 2070 | 2.2% | (10.2)% | 12.4% |
| &nbsp;&nbsp;&nbsp;LACA | 469 | 386 | 21.6% | (2.2)% | 23.8% |
|  | **12742** | **11875** | **7.3%** | **(4.4)%** | **11.7%** |
| &nbsp;&nbsp;Other<sup>6</sup> | (60) | 13 | (+100)% | —% | (+100)% |
| **Net Sales** | $**12682** | $**11888** | **6.7%** | **(4.4)%** | **11.1%** |
| **Emerging Markets**<sup>7</sup> | $**1715** | $**1429** | **20.0%** | **(9.3)%** | **29.3%** |

---

*Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.*

*Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions / divestitures are not prepared in accordance with U.S. GAAP.*

**<u>Guidance for Full Year and First Quarter 2023</u>**

The company estimates net sales growth for the full year 2023, versus the prior year period, to be in a range of approximately 5 to 7 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.11 to $1.21 and estimates adjusted EPS, excluding certain charges (credits) of $1.86 to $1.93.

The company estimates net sales growth for the first quarter of 2023, versus the prior year period, to be in a range of approximately 3 to 5 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. First quarter organic guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.23 to $0.26 and adjusted EPS, excluding certain charges (credits) of $0.42 to $0.44.

**<u>Conference Call Information</u>**

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: <u>www.bostonscientific.com</u>. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

**About Boston Scientific**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit <u>www.bostonscientific.com</u> and connect on <u>Twitter</u> and <u>Facebook</u>.

**Cautionary Statement Regarding Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may", "intend," and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the first quarter and full year 2023; our financial performance; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: the impact of the ongoing COVID-19 pandemic on our operations and financial results; the impact of foreign currency fluctuations; future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

**Note**: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

**Use of Non-GAAP Financial Information**

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

---

| | | | |
|:---|:---|:---|:---|
| CONTACT: | | | |
| Media: | Kate Haranis | Investors: | Lauren Tengler |
| | 508-683-6585 (office) | | 508-683-4479 (office) |
| | Media Relations | | Investor Relations |
| | Boston Scientific Corporation | | Boston Scientific Corporation |
| | <u>kate.haranis@bsci.com</u> | | <u>BSXInvestorRelations@bsci.com</u> |

---

------

**BOSTON SCIENTIFIC CORPORATION**

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
|<br>*in millions, except per share data* | **2022** | **2021** | **2022** | **2021** |
| Net sales | $3242 | $3127 | $12682 | $11888 |
| Cost of products sold | 1011 | 971 | 3956 | 3711 |
| Gross profit | 2231 | 2155 | 8727 | 8177 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 1163 | 1153 | 4520 | 4359 |
| &nbsp;&nbsp;&nbsp;Research and development expenses | 330 | 320 | 1323 | 1204 |
| &nbsp;&nbsp;&nbsp;Royalty expense | 13 | 11 | 47 | 49 |
| &nbsp;&nbsp;&nbsp;Amortization expense | 199 | 192 | 803 | 741 |
| &nbsp;&nbsp;&nbsp;Intangible asset impairment charges |  | 197 | 132 | 370 |
| &nbsp;&nbsp;&nbsp;Contingent consideration net expense (benefit) | (33) | (18) | 35 | (136) |
| &nbsp;&nbsp;&nbsp;Restructuring net charges (credits) | 6 | 23 | 24 | 40 |
| &nbsp;&nbsp;&nbsp;Litigation-related net charges (credits) | 131 | 128 | 173 | 430 |
| &nbsp;&nbsp;&nbsp;Loss (gain) on disposal of businesses and assets | 22 | (30) | 22 | (78) |
|  | 1830 | 1975 | 7078 | 6978 |
| Operating income (loss) | 402 | 180 | 1649 | 1199 |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (64) | (87) | (470) | (341) |
| &nbsp;&nbsp;&nbsp;Other, net | 58 | 26 | (38) | 218 |
| Income (loss) before income taxes | 396 | 120 | 1141 | 1076 |
| &nbsp;&nbsp;&nbsp;Income tax expense (benefit) | 256 | 26 | 443 | 36 |
| **Net income (loss)** | $**140** | $**94** | $**698** | $**1041** |
| &nbsp;&nbsp;&nbsp;Preferred stock dividends | (14) | (14) | (55) | (55) |
| **Net income (loss) available to common stockholders** | $**126** | $**80** | $**642** | $**985** |
| **Net income (loss) per common share - basic** | $**0.09** | $**0.06** | $**0.45** | $**0.69** |
| **Net income (loss) per common share - assuming dilution** | $**0.09** | $**0.06** | $**0.45** | $**0.69** |
| **<u>Weighted-average shares outstanding</u>** |  |  |  |  |
| Basic | 1432.7 | 1425.2 | 1430.5 | 1422.3 |
| Assuming dilution | 1442.4 | 1436.2 | 1439.7 | 1433.8 |

---

------

**BOSTON SCIENTIFIC CORPORATION**

NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** |
|<br>*in millions, except per share data* | **Gross Profit** | **Operating Expenses** | **Operating Income (Loss)** | **Other Income (Expense)** | **Income (Loss) Before Income Taxes** | **Net Income (Loss)** | **Preferred Stock Dividends** | **Net Income (Loss) Available to Common Stockholders** | **Impact per Share**<sup>(1)</sup> |
| **Reported** | $**2231** | $**1830** | $**402** | $**(6)** | $**396** | $**140** | $**(14)** | $**126** | $**0.09** |
| *Non-GAAP adjustments:* |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense |  | (199) | 199 |  | 199 | 175 |  | 175 | 0.12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition / divestitures-related net charges (credits) | 24 | (29) | 53 | (44) | 9 | 59 |  | 59 | 0.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and restructuring-related net charges (credits) | 16 | (12) | 28 |  | 28 | 25 |  | 25 | 0.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation-related net charges (credits) |  | (131) | 131 |  | 131 | 101 |  | 101 | 0.07 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment portfolio net losses (gains) |  |  |  | (38) | (38) | (32) |  | (32) | (0.02) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EU MDR implementation costs | 13 | (6) | 19 |  | 19 | 17 |  | 17 | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax expenses (benefits) |  |  |  |  |  | 42 |  | 42 | 0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discrete tax items |  |  |  |  |  | 129 |  | 129 | 0.09 |
| **Adjusted** | $**2285** | $**1452** | $**833** | $**(88)** | $**745** | $**656** | $**(14)** | $**642** | $**0.45** |
|  | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** |
| *in millions, except per share data* | **Gross Profit** | **Operating Expenses** | **Operating Income (Loss)** | **Other Income (Expense)** | **Income (Loss) Before Income Taxes** | **Net Income (Loss)** | **Preferred Stock Dividends** | **Net Income (Loss) Available to Common Stockholders** | **Impact per Share**<sup>(1)</sup> |
| **Reported** | $**2155** | $**1975** | $**180** | $**(60)** | $**120** | $**94** | $**(14)** | $**80** | $**0.06** |
| *Non-GAAP adjustments:* |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense |  | (192) | 192 |  | 192 | 180 |  | 180 | 0.13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible asset impairment charges |  | (197) | 197 |  | 197 | 171 |  | 171 | 0.12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition / divestiture-related net charges (credits) | 32 | (19) | 50 | (57) | (7) | (4) |  | (4) | (0.00) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and restructuring-related net charges (credits) | 20 | (39) | 58 |  | 58 | 51 |  | 51 | 0.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation-related net charges (credits) |  | (128) | 128 |  | 128 | 98 |  | 98 | 0.07 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment portfolio net losses (gains) |  |  |  | 2 | 2 | 2 |  | 2 | 0.00 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EU MDR implementation costs | 9 | (5) | 14 |  | 14 | 13 |  | 13 | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax expenses (benefits) |  |  |  |  |  | 46 |  | 46 | 0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discrete tax items |  |  |  |  |  | 16 |  | 16 | 0.01 |
| **Adjusted** | $**2216** | $**1396** | $**819** | $**(115)** | $**704** | $**667** | $**(14)** | $**653** | $**0.45** |
| <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(1)</sup> For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. |
| *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* |

---

------

**BOSTON SCIENTIFIC CORPORATION**

NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** |
|<br>*in millions, except per share data* | **Gross Profit** | **Operating Expenses** | **Operating Income (Loss)** | **Other Income (Expense)** | **Income (Loss) Before Income Taxes** | **Net Income (Loss)** | **Preferred Stock Dividends** | **Net Income (Loss) Available to Common Stockholders** | **Impact per Share**<sup>(2)</sup> |
| **Reported** | $**8727** | $**7078** | $**1649** | $**(508)** | $**1141** | $**698** | $**(55)** | $**642** | $**0.45** |
| *Non-GAAP adjustments:* |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense |  | (803) | 803 |  | 803 | 694 |  | 694 | 0.48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible asset impairment charges |  | (132) | 132 |  | 132 | 102 |  | 102 | 0.07 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition / divestitures-related net charges (credits) | 97 | (206) | 303 | (18) | 285 | 338 |  | 338 | 0.24 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and restructuring-related net charges (credits) | 65 | (45) | 110 |  | 110 | 96 |  | 96 | 0.07 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation-related net charges (credits) |  | (173) | 173 |  | 173 | 133 |  | 133 | 0.09 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment portfolio net losses (gains) |  |  |  | (30) | (30) | (28) |  | (28) | (0.02) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EU MDR implementation costs | 46 | (25) | 71 |  | 71 | 62 |  | 62 | 0.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt extinguishment charges |  |  |  | 194 | 194 | 149 |  | 149 | 0.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax expenses (benefits) |  |  |  |  |  | 140 |  | 140 | 0.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discrete tax items |  |  |  |  |  | 129 |  | 129 | 0.09 |
| **Adjusted** | $**8935** | $**5694** | $**3241** | $**(362)** | $**2880** | $**2514** | $**(55)** | $**2459** | $**1.71** |
|  | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** |
| *in millions, except per share data* | **Gross Profit** | **Operating Expenses** | **Operating Income (Loss)** | **Other Income (Expense)** | **Income (Loss) Before Income Taxes** | **Net Income (Loss)** | **Preferred Stock Dividends** | **Net Income (Loss) Available to Common Stockholders** | **Impact per Share**<sup>(2)</sup> |
| **Reported** | $**8177** | $**6978** | $**1199** | $**(123)** | $**1076** | $**1041** | $**(55)** | $**985** | $**0.69** |
| *Non-GAAP adjustments:* |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense |  | (741) | 741 |  | 741 | 676 |  | 676 | 0.47 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible asset impairment charges |  | (370) | 370 |  | 370 | 318 |  | 318 | 0.22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition / divestiture-related net charges (credits) | 65 | 34 | 31 | (482) | (450) | (453) |  | (453) | (0.32) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and restructuring-related net charges (credits) | 79 | (112) | 191 |  | 191 | 169 |  | 169 | 0.12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation-related net charges (credits) |  | (430) | 430 |  | 430 | 331 |  | 331 | 0.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment portfolio net losses (gains) |  |  |  | 181 | 181 | 137 |  | 137 | 0.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EU MDR implementation costs | 32 | (17) | 49 |  | 49 | 45 |  | 45 | 0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax expenses (benefits) |  |  |  |  |  | 132 |  | 132 | 0.09 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discrete tax items |  |  |  |  |  | (5) |  | (5) | (0.00) |
| **Adjusted** | $**8353** | $**5343** | $**3010** | $**(423)** | $**2587** | $**2391** | $**(55)** | $**2336** | $**1.63** |
| <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. | <sup>(2)</sup> For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders. |
| *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* | *An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.* |

---

------

**BOSTON SCIENTIFIC CORPORATION**

Q1 and FY 2023 GUIDANCE RECONCILIATIONS

(Unaudited)

**<u>Net Sales</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Q1 2023 Estimate** | **Q1 2023 Estimate** | **Full Year 2023 Estimate** | **Full Year 2023 Estimate** |
| | **(Low)** | **(High)** | **(Low)** | **(High)** |
| **Reported growth** | **3%** | **5%** | **5%** | **7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Impact of foreign currency fluctuations | (4)% | (4)% | (1)% | (1)% |
| **Operational growth** | **7%** | **9%** | **6%** | **8%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Impact of certain acquisitions / divestitures | 1% | 1% | —% | —% |
| **Organic growth** | **6%** | **8%** | **6%** | **8%** |

---

**<u>Earnings per Share</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Q1 2023 Estimate** | **Q1 2023 Estimate** | **Full Year 2023 Estimate** | **Full Year 2023 Estimate** |
| | **(Low)** | **(High)** | **(Low)** | **(High)** |
| **GAAP results** | $**0.23** | $**0.26** | $**1.11** | $**1.21** |
| Amortization expense | 0.12 | 0.12 | 0.47 | 0.47 |
| Acquisition / divestiture-related net charges (credits) | 0.03 | 0.02 | 0.12 | 0.10 |
| Other adjustments | 0.04 | 0.04 | 0.16 | 0.15 |
| **Adjusted results** | $**0.42** | $**0.44** | $**1.86** | $**1.93** |

---

------

**<u>Use of Non-GAAP Financial Measures</u>**

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share we exclude certain charges (credits), which include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits); and certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission or any Quarterly Report on Form 10-Q that we file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) available to common stockholders and GAAP net income (loss) per common share - assuming dilution, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded

------

from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) available to common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

<br>